CYTARABINE CONJUGATES FOR TREATING CANCER Russian patent published in 2019 - IPC A61K31/7068 A61P35/00 A61P31/12 

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns a method of treating a neoplastic disease involving administering to a subject in need of such treatment a pharmaceutical composition containing a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, wherein said pharmaceutical composition further contains a pharmaceutically acceptable carrier, wherein said compound is astarabine, wherein the therapeutically effective amount of astarabine is a daily dose of 0.5 g/m² up to 10 g/m² body surface area of the subject. Group of inventions also relates to a method of treating a neoplastic disease comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of astarabine, wherein the undesirable events from the above compound are reduced compared to the undesired effects of unconjugated cytarabine, such that the compound can be administered in a dose at least twice the standard dose of cytarabine, and wherein the subject will not experience dose-limiting toxicity, wherein said pharmaceutical composition further contains a pharmaceutically acceptable carrier.

EFFECT: group of inventions provides treating a neoplastic disease.

31 cl, 2 dwg, 2 tbl, 4 ex